ClinicalTrials.gg

Program

pitolisant

Also written as “Pitolisant”, “Open-label Pitolisant” and “Pitolisant Oral Tablet”.

Its studies are mostly in Prader-Willi Syndrome · Idiopathic Hypersomnia · Myotonic Dystrophy · Disorders of Excessive Somnolence · Diabetes Mellitus, Type 1, led by 3 companies.

Furthest: phase 3, since Dec 1, 20218 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Harmony Biosciences62 open or runningphase 3since Dec 1, 2021Jan 29, 2020Apr 2027phase 3 · NCT06366464
Citrine Medicine10 open or runningphase 3since Jan 24, 2022Jan 24, 2022none ahead
High Point Clinical Trials Center10 open or runningphase 1since Jul 17, 2019Jul 17, 2019none ahead

Also a collaborator on its studies: ferox-therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 17, 2019First study: phase 1 study in Diabetes Mellitus, Type 1New to High Point Clinical Trials CenterHigh Point Clinical Trials Center · NCT04026750 · 5 enrolled · United States
  2. Jan 29, 2020Harmony Biosciences's first study: phase 2 study in Prader-Willi SyndromeNew to Harmony BiosciencesHarmony Biosciences · NCT04257929 · 65 enrolled · United States
  3. May 10, 2021Phase 2 study in Myotonic DystrophyHarmony Biosciences · NCT04886518 · 30 enrolled · United States, Canada
  4. Dec 1, 2021Phase 3 study in Idiopathic HypersomniaHarmony Biosciences · NCT05156047 · 214 enrolled · United States
  5. Jan 24, 2022Citrine Medicine's first study: phase 3 study in Disorders of Excessive SomnolenceNew to Citrine MedicineCitrine Medicine · NCT05223166 · 240 enrolled · China
  6. Jul 11, 2022Phase 3 study in Idiopathic HypersomniaHarmony Biosciences · NCT05458128 · 119 enrolled · United States
  7. Oct 9, 2023Phase 3 study in Prader-Willi SyndromeHarmony Biosciences · NCT06366464 · 134 planned · United States, Australia, Belgium and more
  8. Oct 20, 2025Phase 3 study in Prader-Willi SyndromeHarmony Biosciences · NCT07219485 · 150 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 3 study in Prader-Willi SyndromeHarmony Biosciences · NCT06366464
  2. Aug 2030Primary completion: phase 3 study in Prader-Willi SyndromeHarmony Biosciences · NCT07219485

TargetBeta

HRH3 →read by rule
“Histamine H3 receptor inverse agonist; Histamine H3 receptor inverse agonist”ChEMBL 37, by rule

Other programs on HRH3

ProgramCompanyFurthest phaseStudies
samelisantrulesuven-life-sciences-limitedphase 33

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07219485Prader-Willi Syndrome · United States3By invitationHarmony BiosciencesAug 2030150
NCT06366464Prader-Willi Syndrome · United States, Australia, Belgium and more3RecruitingHarmony BiosciencesApr 2027134
NCT05458128Idiopathic Hypersomnia · United States3CompletedHarmony BiosciencesOct 1, 2025119
NCT05223166Disorders of Excessive Somnolence · China3CompletedCitrine MedicineJul 18, 2023240
NCT05156047Idiopathic Hypersomnia · United States3CompletedHarmony BiosciencesSep 8, 2023214
NCT04886518Myotonic Dystrophy · United States, Canada2CompletedHarmony BiosciencesOct 6, 202330
NCT04257929Prader-Willi Syndrome · United States2CompletedHarmony BiosciencesAug 17, 202265
NCT04026750Diabetes Mellitus, Type 1 · United States1TerminatedHigh Point Clinical Trials CenterFeb 16, 20205

How it is read

Names in the registry

  • “Pitolisant”, 4 entries
  • “Open-label Pitolisant”, 1 entry
  • “Pitolisant Oral Tablet”, 1 entry
  • “Pitolisant tablet”, 1 entry
  • “Pitolisant oral tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.